Female Hair Loss Treatment: What Actually Works

How Common Is Hair Loss in Women?

Hair thinning in women is common and probably underreported, since many women never bring it up at a visit. A population-based study of an Australian community found FPHL affected 19% of women in their 30s, rising to 37.8% of women aged 70 and older [1]. Prevalence climbs steadily with age and accelerates around menopause.

Unlike male pattern baldness, which produces a receding hairline and vertex balding, women typically lose density diffusely across the crown and part line while the frontal hairline stays intact. The Ludwig classification grades this thinning from grade I (mild widening of the central part) through grade III (near total loss over the crown) [2]. The pattern matters clinically: a dermatologist seeing diffuse shedding without follicle miniaturization will suspect telogen effluvium or a systemic cause rather than FPHL.

Hair cycling also differs by sex. Women tend to have a longer anagen (growth) phase, contributing to longer baseline hair length. When that cycle is disrupted, whether by androgen sensitivity, nutritional deficits, or inflammation, the anagen phase shortens and the telogen (resting) phase lengthens, producing visible thinning over months [3].

What Causes Female Pattern Hair Loss?

FPHL involves genetic susceptibility and androgen activity at the follicle, but the hormonal picture in women is less straightforward than the DHT-driven story typically described in men. Many women with FPHL have entirely normal circulating androgen levels, which suggests that local enzyme activity in scalp tissue, particularly 5-alpha reductase and aromatase expression, plays a larger role than serum testosterone [4].

Androgen excess is not required to diagnose FPHL. A woman can have normal hormone labs and still carry a confirmed FPHL diagnosis based on dermoscopy findings such as follicular miniaturization, variable hair shaft diameter, and perifollicular brown halos [5]. When PCOS or another hyperandrogenic condition is present alongside hair loss, it changes the workup and treatment approach, but its absence does not rule FPHL out.

Genetics matter substantially. A family history of thinning on either the maternal or paternal side raises risk. Twin studies in men have estimated heritability of androgenetic alopecia above 80% [6]; women with FPHL are believed to share much of that genetic risk with affected relatives, though sex-specific heritability has been studied less directly. Environment, hormones, and nutrition then determine how and when that genetic susceptibility shows up.

Telogen Effluvium: The Other Major Cause

Telogen effluvium (TE) accounts for a large share of acute shedding complaints in women. It occurs when a physiologic stressor pushes a disproportionate number of follicles from anagen into telogen at once. Two to four months later, those hairs fall out in noticeable quantities.

Common triggers include [7]:

• Childbirth (postpartum TE is thought to affect roughly 40 to 50% of new mothers)
• Crash dieting or rapid weight loss, including after starting a GLP-1 agonist
• Major surgery or hospitalization
• High fever, including reported post-COVID shedding
• Thyroid dysfunction, both hypo- and hyperthyroidism
• Iron deficiency, even without frank anemia
• Discontinuation of oral contraceptives

The hallmark of TE is diffuse shedding without miniaturization. A gentle hair pull test that yields more than a few telogen hairs supports the diagnosis. Classic acute TE is self-limiting: once the trigger resolves, regrowth begins within 3 to 6 months and density typically normalizes by 12 to 18 months [7]. Chronic TE, meaning shedding that persists beyond 6 months, warrants a more thorough metabolic and hormonal workup rather than reassurance alone.

Which Pattern Matches What You're Seeing?

This is not a diagnosis and does not replace an exam, but it can help focus what to bring up with a clinician and what to check first.

If more than one row fits, or if the picture is unclear, that itself is a reason to get an in-person evaluation rather than guess.

The Lab Workup Many Women Should Consider

Before starting treatment, a directed laboratory evaluation can identify reversible contributors. Reviews of FPHL and TE commonly recommend a baseline panel along these lines [8]:

Thyroid function. TSH and free T4. Even subclinical hypothyroidism can produce diffuse thinning before other symptoms appear.

Iron stores. Serum ferritin is the most useful single marker. Reviews of micronutrient factors in hair loss point to iron status as a modifiable contributor to shedding [9], and many dermatologists target ferritin above 40 ng/mL, with some aiming for 70 ng/mL, though this specific threshold comes from clinical practice more than a randomized trial. Checking ferritin alongside a CBC helps distinguish iron deficiency from iron deficiency anemia.

Androgens. Total testosterone, free testosterone, and DHEA-S. An elevated free testosterone or DHEA-S can point toward PCOS or an adrenal source and changes the treatment approach.

Vitamin D. 25-hydroxyvitamin D. Observational studies have linked levels below 30 ng/mL with both TE and FPHL, though causality remains debated [10].

Additional tests when indicated. ANA if alopecia areata is suspected, plus zinc, B12, prolactin, or a comprehensive metabolic panel if systemic disease is on the differential.

A normal workup does not mean nothing is wrong. It means FPHL driven by local follicular androgen sensitivity is the more likely explanation.

FDA-Approved Treatment: Topical Minoxidil

Topical minoxidil is the first-line, FDA-approved treatment for FPHL. Minoxidil's efficacy as a topical foam was first established in placebo-controlled trials in men [11], and the 5% foam later received FDA clearance for women in 2014. A randomized trial comparing 5% foam once daily against 2% solution twice daily in women found significantly greater increases in non-vellus hair count with the 5% foam, along with less scalp irritation, since the foam formulation omits propylene glycol [12].

Application: about one capful applied directly to the dry scalp along the part line once daily. It needs to contact the scalp, not just the hair shafts. Initial shedding during weeks 2 through 8 is common and generally signals a therapeutic response, as miniaturized telogen hairs are pushed out by new anagen growth.

Minoxidil is not a cure. It requires continuous use, and clinical experience along with product labeling indicates that gains fade within several months of stopping. Treat it as ongoing maintenance rather than a fixed course.

Off-Label Treatments With Supporting Evidence

Spironolactone

Spironolactone, an aldosterone antagonist with anti-androgen effects, is the most widely prescribed off-label oral therapy for FPHL. It blocks androgen receptors in the hair follicle and reduces adrenal androgen production.

A retrospective review of women treated with spironolactone found that the large majority experienced stabilization or improvement in shedding by 12 months [13], though response rates vary across studies and individuals. Spironolactone is well established in dermatology practice for FPHL, but it is contraindicated in pregnancy because of a theoretical risk of feminizing a male fetus, and reliable contraception is generally advised during use [5].

Common side effects include orthostatic lightheadedness, breast tenderness, and menstrual irregularity. Potassium monitoring is reasonable at baseline and after dose changes, though clinically significant hyperkalemia is uncommon in healthy young women. Clinicians who prescribe it regularly note that the bigger barrier tends to be patience: most women need to commit to at least 12 months before judging whether it is working.

Low-Dose Oral Minoxidil

Oral minoxidil at doses of 0.25 to 2.5 mg daily has become a common option for women who find topical application impractical or who develop scalp irritation. A review of oral minoxidil for hair loss describes clinically meaningful regrowth in a substantial share of patients with FPHL across the accumulated literature, with hypertrichosis, meaning unwanted facial or body hair, as the most frequent side effect at higher doses [14].

Because minoxidil is a vasodilator, checking blood pressure at baseline and periodically is reasonable, although hemodynamic effects at these low doses appear minimal in people without hypertension. A separate study of oral minoxidil in chronic telogen effluvium reported symptomatic improvement in shedding without describing significant cardiovascular effects, though that population and this one overlap only partly, and individual response should be confirmed with a prescribing clinician rather than assumed from trial data [15].

Platelet-Rich Plasma (PRP)

PRP involves drawing the patient's blood, concentrating the platelet fraction, and injecting it into the scalp. A meta-analysis of randomized controlled trials found PRP-treated areas had significantly greater hair density and thickness than placebo-treated areas [16]. A separate split-scalp randomized trial, where PRP was injected into one half of the scalp and a control substance into the other half of the same patient, found the PRP-treated side had greater hair density [17]. Protocols vary widely, with most studies using 3 to 4 monthly sessions followed by maintenance every 3 to 6 months.

PRP is generally used as an adjunct to topical or oral therapy rather than as a standalone treatment. Whether adding PRP produces a meaningfully additive benefit on top of minoxidil specifically has not been established by a dedicated combination trial in the sources reviewed here, so that claim should be treated as plausible but unconfirmed rather than settled.

Hormonal Hair Loss: Menopause, PCOS, and Postpartum

Menopause

The perimenopausal transition can accelerate FPHL as estrogen declines and androgen influence becomes relatively more prominent. Estrogen supports the anagen phase directly, so its loss can shorten the growth cycle. The North American Menopause Society's 2022 position statement addresses hormone therapy considerations during menopause, including that hair changes are a recognized and often distressing symptom [18].

Hormone therapy with systemic estradiol may slow menopause-related thinning, particularly when paired with a non-androgenic progestogen such as micronized progesterone or drospirenone. Progestins with more androgenic activity, such as medroxyprogesterone acetate or norethindrone, can worsen hair loss and are generally best avoided in women with FPHL who are considering hormone therapy [18]. This is a discussion to have directly with a prescriber, since it involves individualized risk and benefit beyond hair alone.

PCOS

Polycystic ovary syndrome affects a meaningful share of reproductive-age women, and hair loss is among its more psychologically difficult symptoms [19]. Androgen excess directly miniaturizes susceptible follicles. Combined oral contraceptives containing anti-androgenic progestins, such as drospirenone, paired with spironolactone, form a common approach. Metformin alone has not shown consistent benefit for hair outcomes in PCOS trials, though it may help when insulin resistance is a dominant feature of the presentation [19].

Postpartum Shedding

Postpartum TE results from the synchronized shift of follicles that stayed in anagen during pregnancy's high-estrogen state. The shedding can be dramatic but is temporary and does not usually require pharmacologic treatment. Ensuring adequate iron stores, continuing prenatal vitamins, and reassurance that regrowth typically returns by 6 to 12 months postpartum is the standard approach [7].

GLP-1 Agonists and Hair Loss: What the Data Show

Hair shedding during semaglutide and tirzepatide treatment has drawn attention. In the STEP-1 trial (N=1,961), alopecia was reported by 3.0% of participants on semaglutide 2.4 mg versus 1.0% on placebo [20]. The mechanism is almost certainly rapid-weight-loss-induced TE rather than a direct drug effect on the follicle, since any fast weight loss, surgical or pharmacologic, can trigger telogen conversion.

The SURMOUNT-1 trial of tirzepatide (N=2,539) reported alopecia in roughly 4.9 to 5.7% of active treatment groups compared to 0.9% on placebo, with higher rates in groups that lost more weight [21]. Women starting a GLP-1 agonist can be counseled that shedding typically peaks around months 3 to 6 and tends to self-resolve as weight stabilizes. Adequate protein intake (roughly 1.0 to 1.2 g/kg/day) and iron sufficiency may help limit severity, though this has not been tested as a dedicated prevention strategy in trials.

When to See a Specialist

Primary care can reasonably manage straightforward TE and initiate minoxidil for mild FPHL. Referral to a dermatologist with hair-loss expertise is appropriate when:

• The pattern is atypical: patchy, scarring, or rapidly progressive
• Ludwig grade II or III is present on examination
• Labs suggest an endocrine disorder that needs subspecialty input
• First-line therapy has been tried consistently for 12 months without benefit
• Scalp biopsy is needed to distinguish FPHL from chronic TE or early scarring alopecia

Trichoscopy, meaning dermoscopic examination of the scalp, can often be performed in-office and provides enough diagnostic detail to avoid a biopsy. Hair diameter diversity greater than 20%, yellow dots, and peripilar signs are relatively specific findings for FPHL [22].

Building a Treatment Timeline

Expect no visible change before month 3 for any treatment. Standardized photography at baseline, 6 months, and 12 months is the most objective way to track progress, since day-to-day mirror checks are unreliable. Minoxidil and spironolactone both typically need 6 to 12 months to reach peak effect. Women who add PRP often see incremental gains starting a few months after the initial session series. Rechecking ferritin around 3 months after starting supplementation confirms whether iron repletion is on track, with a common target of ferritin above 50 ng/mL and stable hemoglobin.